HC Wainwright & Co. Reiterates Buy on Monopar Therapeutics, Maintains $105 Price Target

Monopar Therapeutics

Monopar Therapeutics

MNPR

0.00

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Monopar Therapeutics (NASDAQ: MNPR) with a Buy and maintains $105 price target.